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Abstract 
Background: Schizophrenia is a chronic condition negatively influencing quality of life of 
affected people.  Evidence exists that there is increased prevalence of metabolic syndrome in 
people with schizophrenia.  Current medications used in treating schizophrenia have been 
implicated in further exacerbating this already increased baseline prevalence of metabolic 
syndrome in schizophrenia patients, specifically second generation antipsychotic agents more 
than first generation antipsychotic agents.  This connection between developing metabolic 
syndrome and use of second generation antipsychotic agents is still being clarified. 
Objective:  To systematically review available evidence on the incidence of developing 
metabolic syndrome in patients with schizophrenia being treated with second generation 
antipsychotic agents versus those treated with first generation antipsychotic agents.   
Methods: In order to review available evidence, this author searched MEDLINE, CINAHL, The 
Cochrane Library, and BIOSIS (January 1990 to May 2011) using MeSH terms such as 
“antipsychotic agents” and “metabolic syndrome.”  Additional articles were identified through a 
hand search of reference lists of selected articles. 
Results:  The initial literature search identified 326 articles.  After abstract review, 9 articles 
underwent full text review, and finally 2 studies were included into the review after applying 
inclusion and exclusion criteria.  The results of these 2 studies indicate fair to poor quality 
evidence of increased incidence of developing metabolic syndrome in patients with 
schizophrenia being treated with second generation antipsychotic agents when compared to 
patients with schizophrenia treated with first generation antipsychotics. 
Conclusion:  This review identified that there is an overall lack of adequate studies to properly 
answer the question posed.  The studies included in this review suffered from several limitations 
lessening the utility of their findings.  Therefore, future research is needed to determine the effect 
of second generation antipsychotic agents on developing metabolic syndrome when compared to 
first generation antipsychotic agents.   
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Introduction 
A. Purpose 
Schizophrenia and metabolic syndrome are chronic conditions that have a significant effect 
on the quality of life of those affected.  There is evidence of increased prevalence of 
metabolic syndrome in those with schizophrenia 1.  More recently, researchers and clinicians 
have questioned whether the pharmacotherapies used to treat persons with schizophrenia play 
a role in the development of metabolic syndrome.  Additionally, researchers, and clinicians 
need to know if there are differential contributions to the risk for metabolic syndrome 
induced by different classes of medications.  This paper will attempt to evaluate the research 
thus far to determine whether there is a differential contribution of second generation 
antipsychotics versus first generation antipsychotics.   
 
B. Background 
Metabolic syndrome  
Metabolic syndrome as it is known today consists of a constellation of risk factors including 
central obesity, hyperglycemia, hypertension, and dyslipidemia.  These components of 
metabolic syndrome lead to end organ damage resulting in cardiovascular disease, 
retinopathy, neuropathy, renal disease and amputations 2.  This causes significant morbidity 
that can greatly reduce quality of life.   
 
There are several definitions of metabolic syndrome which all share similar characteristics 
however; there is some variance in the relative importance given to certain diagnostic 
criteria.  Two commonly used definitions for metabolic syndrome are the adapted National 
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Cholesterol Education Program Adult Treatment Panel III criteria by the American Heart 
Association (NCEP ATP IIIa) and the International Diabetes Federation (IDF) 3, 4. 
 
Utilizing the NCEP ATP IIIa criteria, metabolic syndrome is diagnosed when 3 or more of 
five criteria are met: elevated waist circumference (≥40 inches in men and ≥ 35 inches in 
women), elevated fasting triglycerides (≥150mg/dL), reduced HDL (<40 mg/dL in men and 
<50 mg/dL in women), elevated blood pressure (≥130/85 mm Hg) or taking antihypertensive 
medication, and elevated fasting glucose (≥100 mg/dL) or taking insulin or hypoglycemic 
medication.  The only difference between original NCEP ATP III criteria and the adapted 
version (NCEP ATP IIIa) was that the original criteria used the older threshold of elevated 
fasting glucose at ≥110 mg/dL and the adapted version changed this criterion based on the 
American Diabetes Association lowering the criteria for elevated fasting glucose to ≥100 
mg/dL.   
 
The IDF criteria require the presence of central adiposity (elevated waist circumference) 
which is defined using ethnicity specific values 4.  In addition, two of four other criteria also 
need to be present for diagnosis of metabolic syndrome.  These four criteria (elevated fasting 
triglycerides, reduced HDL, elevated blood pressure, and elevated fasting glucose) are 
defined in the same way as the NCEP ATP IIIa definition.   As these definitions are very 
similar, I will use both definitions in this review in order to be more inclusive of results.  
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Schizophrenia 
Schizophrenia is a chronic and debilitating mental illness affecting 1% of the world’s 
population 2.  Symptoms of schizophrenia include positive symptoms (delusions, 
hallucinations, disorganized speech, negative symptoms (flattened affect, alogia, and 
avolition), and neurocognitive deficits (attention impairment, memory deficits, executive 
dysfunction). 
 
Patients with schizophrenia when compared to the general population have a shorter life 
span.   The reasons for this are currently under study.  Although persons with schizophrenia 
have a higher prevalence of suicide attempts as well as successful suicides, a majority of 
persons with schizophrenia die of coronary heart disease, an endpoint of metabolic syndrome 
5.  Furthermore, the prevalence of coronary heart disease is also higher in patients with 
schizophrenia than in the general population 5.   
 
De Hert, Schreurs, Vancampfort et al. conducted a review of thirty-eight studies on the 
association of metabolic syndrome in people with schizophrenia.  They found that the 
increased prevalence and incidence of metabolic syndrome in people with schizophrenia is 
approximately 2 to 3 times greater than in the general population 1.  This increased risk is 
theorized to be due to several causes including aspects of schizophrenia itself, lifestyle 
issues, genetics, and finally, antipsychotic medications.    
 
Those with schizophrenia tend to have a sedentary lifestyle without much physical activity, 
improper nutrition, and substance abuse especially tobacco abuse 2.  Aspects of schizophrenia 
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such as the negative symptoms and increased stress levels further contribute to these lifestyle 
issues 1.    In combination, these lifestyle factors can easily result in weight gain and obesity, 
hypertension, and dyslipidemia, all of which are components of metabolic syndrome.   
 
The involvement of genetics in the association between schizophrenia and metabolic 
syndrome has been purported as studies have shown that there is an increased risk of 
metabolic dysregulation, specifically diabetes and glucose intolerance, in first degree 
relatives of people with schizophrenia 1, 6. 
 
Schizophrenia treatment 
Treatment for schizophrenia involves the use of antipsychotic medications.  These 
medications can be divided into two groups: first generation or typical antipsychotics, and 
second generation or atypical antipsychotics.  
 
First generation antipsychotics are older, and mainly target positive symptoms.  They are 
distinguished by their high affinity for blocking D2 dopamine receptors in the brain which is 
directly related to their ability to target and treat positive symptoms.  However, they have a 
significant side effect profile involving movement related side effects such as: parkinsonism 
(rigidity or difficulty initiating movements), dystonia (strong involuntary muscle 
contractions), akithisia (inner motor restlessness resulting in the inability to sit still and 
causing patients to feel they need to move to be comfortable), and tardive dyskinesia 
(abnormal involuntary movements that persist and can be stigmatizing or, in more severe 
cases, can cause functional difficulties).  Furthermore, some first generation antipsychotics 
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have been noted to cause weight gain 7.  Due to these side effects, there is concern that first 
generation antipsychotics are not well tolerated when used for long periods of time.   
 
Second generation antipsychotics are newer, target positive symptoms and may result in 
fewer secondary negative symptoms.  Several of these drugs entered the market in the 1990s 
and quickly gained popularity.  They have a different side effect profile than the first 
generation antipsychotics as they have a reduced incidence of movement related side effects.  
In some of the second generation antipsychotic medications, this has been attributed to their 
decreased affinity for D2 dopamine receptors and utilization of other neurotransmitter 
systems, such as the serotonin system.  They are currently the first-line therapeutic agents 
used in those presenting with symptoms of schizophrenia.    
 
It has been discovered, however, that these second generation antipsychotics can contribute 
to metabolic side effects including weight gain, dyslipidemia, and impaired glucose 
regulation 3.  Pramyothin and Khaodhiar conducted a review of current literature evaluating 
the effect of various second generation antipsychotic medications on individual metabolic 
criteria 6.  They found that of the seven commonly prescribed second generation 
antipsychotics (clozapine, olanzapine, risperidone, quetiapine, aripiprazole, ziprasidone, 
amisulpride), two (olanzapine and clozapine) were most associated with increased weight 
gain, increased risk for diabetes and a worsening lipid profile. Of these factors, the two 
medications had the most effect on weight gain.  These results suggest that different second 
generation antipsychotics have differential effects on weight and metabolic regulation 6.   
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Schizophrenia, in some cases, can be a truly devastating illness on its own and, when 
compounded with potential adverse effects of antipsychotic medications can further diminish 
the quality of life of those affected.   
 
C. Rationale for systematic review 
Persons with schizophrenia have a higher risk of developing coronary heart disease and 
metabolic syndrome when compared to the general population.  It is important to determine 
whether using second generation antipsychotics increases the risk of metabolic syndrome 
beyond the already elevated baseline risk in schizophrenia patients, and how this risk 
compares to the risk conferred by first generation antipsychotic agents.   
 
The inclusion of metabolic syndrome in the psychiatric literature is recent.  The first study 
detailing metabolic syndrome in patients with schizophrenia was published in 20031.  The 
connection between second generation antipsychotics and metabolic syndrome is even more 
contemporary as their general use has been popular only for the past two decades. As such, 
the long term complications of these medications are just now being realized and the question 
of their implication in increasing the risk of metabolic syndrome is concerning.   
 
Several prevalence studies have been conducted comparing metabolic syndrome in people 
treated with first versus those treated with second generation antipsychotics.  Most of these 
studies are cross sectional with very few randomized controlled trials and prospective cohort 
trials.  In one study, Saddichha, Manjunatha, Ameen et al. conducted a short term 
randomized controlled trial on consecutively admitted patients with a first episode of 
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schizophrenia 8.  These patients were randomized to treatment with olanzapine, risperidone, 
or haloperidol.  Baseline measures were completed prior to the start of treatment with 
antipsychotic medication and follow up measures were completed at 6 weeks which was the 
end of the study period.  
 
The authors calculated prevalence of metabolic syndrome using NCEP ATP III and IDF for 
each of the treatment groups.  Prevalence of metabolic syndrome in those treated with 
olanzapine was 20.0% (NCEP ATP III) and 25.7% (IDF) at the end of the trial.  Prevalence 
of metabolic syndrome in those treated with risperidone was 9.1% (NCEP ATP III) and 
24.2% (IDF) at the end of the trial.  Prevalence of metabolic syndrome in those treated with 
haloperidol was 0% (NCEP ATP III) and 3.2% (IDF) at the end of the trial.   
 
In one cross sectional study conducted in outpatient clinics in northern England, Mackin, 
Watkinson, and Young found that 11.6% of subjects on second generation antipsychotics had 
metabolic syndrome but 0% of those on first generation antipsychotic medication had 
metabolic syndrome 9.   
 
In another cross sectional study in long term patients at psychiatric rehabilitation facilities in 
Australia, Tirupati and Chua found that the prevalence of metabolic syndrome in those taking 
only one first generation antipsychotic and second generation antipsychotic was 66% and 
60.3% respectively10.  The prevalence of metabolic syndrome is high in both first and second 
generation antipsychotic treated groups; however this study was conducted in people with 
long standing psychiatric disease as well as long term treatment with antipsychotic 
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medications.  Furthermore, patients who were treated with first generation antipsychotics 
may have previously been treated with second generation antipsychotics which may 
confound the study and lead to a decreased sensitivity of the study to find differences in the 
influence of first- and second generation antipsychotics on the prevalence of metabolic 
syndrome. 
 
The results of these prevalence studies are concerning.  However, these studies are not able 
to causally indicate whether second generation antipsychotics confer an increased risk in 
developing metabolic syndrome in comparison to first generation antipsychotics.   
 
This emerging problem within the population of those with schizophrenia needs to be 
understood.  Therefore, a systematic review of available literature is needed to determine 
whether treatment with second generation antipsychotics in patients with schizophrenia 
results in an increased incidence of metabolic syndrome in comparison to first generation 
antipsychotics. 
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Methods 
A. Focused Question 
This systematic review seeks to answer the question: “Do patients with schizophrenia 
treated with second-generation antipsychotics have an increased incidence of developing 
metabolic syndrome when compared to patients with schizophrenia treated with first-
generation antipsychotics?”   
 
Past studies have focused on the difference in prevalence of metabolic syndrome between 
those treated with first generation antipsychotics and those treated with second generation 
antipsychotics.  Although, prevalence is an important measure, incidence gives us more 
information about the development of metabolic syndrome itself and provides a way to 
measure the attributable burden of antipsychotic agents.   
 
B. Eligibility Criteria  (Table 1) 
For the purposes of this review, the included articles had to describe a study comparing 
the development of metabolic syndrome of at least one first and one second generation 
antipsychotic agent in people with schizophrenia.  There is data indicating that some of 
the most commonly used second generation antipsychotic medications, specifically 
olanzapine and clozapine, seem to have the greatest effect on individual metabolic 
parameters (weight gain, impaired fasting glucose) 6.  Furthermore, some of the 
remaining commonly used second generation antipsychotic medications (risperidone, 
quetiapine) also have a moderately increased effect on individual metabolic parameters as 
well 6.  Therefore, since many of the commonly prescribed second generation 
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antipsychotics have been implicated in causing metabolic abnormalities, this paper will 
focus on examining second generation antipsychotic medications as a group instead of 
specifying a few drugs from the first- and second-generation groups to compare.   
   
The second generation antipsychotics were introduced in the United States starting with 
Clozapine, in 1990.  Therefore, to meet inclusion criteria, articles must have been 
published between January 1990 and May 2011.  Case reports and cross-sectional studies 
were ineligible for this review as they would not be able to measure incidence.  Study 
types eligible for inclusion were randomized controlled trials (RCTs) and cohort studies 
(retrospective and prospective) as these study types could potentially measure incidence.   
 
Studies that only evaluated specific metabolic effects of antipsychotic medications were 
excluded from the review.  These studies generally concentrate on changes in individual 
metabolic parameters such as weight gain, lipid level changes, or insulin resistance which 
would not be appropriate for answering the question proposed in this systematic review.  
Furthermore, studies had to define metabolic syndrome using criteria set forth by the 
American Heart Association adapted  National Cholesterol Education Program Adult 
Treatment Panel III (NCEP ATP IIIa) or the International Diabetes Federation (IDF) 
(Table 2). 
 
The study population in the included studies had to include people with schizophrenia.  If 
the study population included people with schizophrenia as well as others with psychotic 
disorders, the study was eligible for review if the investigators elucidated the proportion 
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of people in the study with schizophrenia.  Current recommendations by the American 
Diabetes Association, the American Psychiatric Association, the American Association 
of Clinical Endocrinologists, and the North American Association for the Study of 
Obesity recommend monitoring of lipids after 12 weeks of treatment by second 
generation antipsychotic medications, therefore treatment duration of at least three 
months was required for inclusion into this review 11.  
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Table 1. Eligibility Criteria 
 Inclusion Exclusion 
Population People with schizophrenia on 
antipsychotic agents 
All others on antipsychotic agents 
Intervention Second generation antipsychotics 
Comparison group First generation antipsychotics  
Outcome Metabolic syndrome Studies measuring only individual 
metabolic syndrome criteria 
Exposure time ≥3 months <3 months 
Search period January 1990-May 2011 Prior to January 1990 
Study design Randomized controlled trials 
Prospective cohort studies 
Retrospective cohort studies 
Cross sectional studies 
Case reports 
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Table 2. Definitions of Metabolic syndrome 
American Heart Association adapted 
National Cholesterol Education Program 
Adult Treatment Panel III (NCEP ATP 
IIIa) criteria 3 
International Diabetes Federation 
(IDF)criteria 4 
 
Three of following five criteria required for 
diagnosis of metabolic syndrome: 
1. Elevated waist circumference (≥102 cm 
in men and ≥ 88 cm in women) 
2. Elevated fasting triglycerides 
(≥150mg/dL) 
3. Reduced HDL (<40 mg/dL in men and 
<50 mg/dL in women) 
4. Elevated blood pressure (≥130/85 mm 
Hg) or on antihypertensive medication 
5. Elevated fasting glucose (≥100 mg/dL) 
or on insulin or hypoglycemic 
medication 
Required: Elevated waist circumference 
according to ethnicity specific values (Table 3) 
AND 
Two of the following four criteria required for 
diagnosis of metabolic syndrome: 
1. Elevated fasting triglycerides 
(≥150mg/dL) or specific treatment for 
this lipid abnormality 
2. Reduced HDL (<40 mg/dL in men and 
<50 mg/dL in women) or specific 
treatment for this lipid abnormality 
3. Elevated blood pressure (≥130/85 mm 
Hg) or on antihypertensive medication 
4. Elevated fasting glucose (≥100 mg/dL) 
or on insulin or hypoglycemic 
medication 
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Table 3. Ethnic specific values for waist circumference 
Country/Ethnic group Waist circumference 
Europoids 
For USA, ATP III values (≥102 cm 
males; ≥88 cm female) are likely to 
continue to be used for clinical 
purposes 
Male ≥ 94cm 
Female ≥ 80 cm 
South Asians Male ≥ 90 cm 
Female ≥ 80 cm 
Chinese Male  ≥ 90 cm 
Female ≥ 80 cm 
Japanese Male  ≥ 90 cm 
Female ≥ 80 cm 
Ethnic South and Central 
Americans 
Use South Asian recommendations until data is 
available 
Sub-Saharan Africans Use European data until data is available 
Eastern Mediterranean and Middle 
East (Arab) populations 
Use European data until data is available 
Adapted from Table 2 of IDF Consensus Worldwide Definition of the Metabolic Syndrome 
booklet. 4 
  
 
17 
C. Search strategy 
I searched four electronic databases including MEDLINE via PUBMED, BIOSIS, 
Cumulative Index to Nursing and Allied Health (CINAHL), and The Cochrane Library 
(Appendix 1).  These databases were chosen on the recommendation of a health sciences 
librarian.  I used Medical Subject Headings (MeSH) terms when possible and used key 
word searches where applicable (Table 4).  These terms were then combined in several 
ways with Boolean operators.  The searches were then limited to articles written in the 
“English Language.”   
 
The search criteria were limited to articles published between January1990 to May 2011.  
Additional articles were identified using a hand search of reference lists of select articles.  
Reference lists of review articles on metabolic syndrome in schizophrenia patients were 
manually searched for other relevant citations.  
 
All of the citations were imported into the citation manager RefWorks.  Within 
RefWorks, citations were consolidated and duplicate articles from the various database 
searches were discarded.  
Table 4. Key words used in database searches 
Key Words 
Antipsychotic agents 
Atypical OR Second generation 
Metabolic syndrome 
Metabolic syndrome X 
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D. Study Selection  
I reviewed all abstracts resulting from the database and hand searches. For a systematic 
review, in an ideal situation, there would have been at least another reviewer, however, 
for this review, I was the solitary reviewer.   I then attempted to retrieve full text articles 
corresponding to abstracts meeting the initial inclusion criteria using online and text 
resources from the University of North Carolina at Chapel Hill, Duke University and 
North Carolina State University.  Retrieved full text articles underwent review and data 
abstraction.   
 
E. Data Abstraction and Synthesis 
A standardized data abstraction form was created using Microsoft Excel in order to be 
consistent and comprehensive when conducting quality assessments and analysis of 
results.  I abstracted the following data from each included study: study type; year study 
was conducted; location; study population; description of intervention; sampling method; 
number of participants; type of comparison group; measured outcomes; length of follow 
up; definition of metabolic syndrome used; potential study bias; description of internal 
and external validity; overall quality of the study.   
 
I created standardized evidence tables to describe the included studies and answer the 
proposed question.  Findings of the review were qualitatively synthesized instead of 
quantitatively (meta-analysis) due to the small number of studies that met inclusion 
criteria and the methodological heterogeneity of the included studies.  In particular I 
 
19 
concentrated on the available evidence for the question presented in this review and the 
overall consistency of the evidence.   
 
F. Quality Assessment 
The quality of the evidence, internal validity, and external validity assessments of each of 
the articles was made using criteria adapted from the United States Preventive Services 
Task Force (USPSTF) of the Agency for Healthcare Research and Quality (AHRQ).  
Tables 5 and 6 describe the specific criteria for internal and external validity respectively.  
Table 7 describes how overall quality was determined based on internal and external 
validity ratings.    
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Table 5.  Criteria for assessing internal validity adapted from USPSTF 12 
Criteria 1. Initial assembly of comparable groups. 
a. RCT: Randomization adequate, equal distribution potential 
confounders 
b. Cohort: considered potential confounders and adequately 
adjusted for these  
2. Maintenance of comparable groups throughout study. 
3. Important differential loss to follow-up or overall high loss to 
follow-up. 
4. Measurements are equal, valid, and reliable 
5. Clear definition of interventions 
6. Outcomes are clearly defined and all important outcomes are 
considered 
7. Analysis:  
a. RCT: Intention to treat analysis  
b. Cohort: Adjustment for potential confounders 
Ratings Good: Meets all criteria; Initial groups are comparable and maintained 
throughout the study; reliable and valid measurement instruments are used 
and applied equally to groups; interventions are spelled out clearly; all 
important outcomes are considered; appropriate attention to confounders in 
the analysis.  For RCTs, an intention to treat analysis is used.   
 
Fair: Generally comparable groups initially assembled; some differences 
with follow-up; measurement instruments are acceptable and generally 
applied equally; some but not all important outcomes are considered; some 
but not all confounders are accounted for.  For RCTs, an intention to treat 
analysis is used.   
 
Poor:  Studies given this rating have any of the following fatal flaws.  
Groups assembled initially are not close to being comparable or 
maintained; unreliable or invalid measurement instruments used or not 
applied equally among groups; key confounders are given little to no 
attention.  For RCTs, intention to treat analysis is lacking.   
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Table 6. Criteria for assessing external validity adapted from USPSTF 12 
Criteria 1. Study population: The degree to which the people who were involved as 
subjects in the study constitute a special population because they were 
selected from a larger eligible population.  The following are features of 
the study population and the study design that may cause experience in 
the study to be different from what would be observed in the general 
population. 
a. Demographics: age, gender, ethnicity, education, income 
b. Comorbidities: frequency of co-morbid conditions in study 
population 
c. Refusal rate: refusal rate among eligible study subjects is high, 
making the enrollees in the study unrepresentative 
d. Adherence: run-in phase, frequent contact to monitor adherence; 
features of the study itself that make study participants comply 
with intervention that may be different than in a clinically 
observed population 
e. Stage in natural history of the disease 
f. Source and intensity of recruitment: The sources for recruiting 
subjects for the study and/or the effort and intensity of 
recruitment may distort the characteristics of the study subjects in 
ways that could increase the effect of the intervention as it is 
observed in the study. 
2. Situation: The degree to which the clinical experience in the situation in 
which the study was conducted is likely to be reproduced in other 
settings. 
3. Providers: The degree to which the providers in the study have the skills 
and expertise likely to be available in general settings 
Ratings Good: The study differs minimally from the US primary care 
population/situation/providers and only in ways that are unlikely to affect 
the outcome; it is highly probable (>90%) that the clinical experience with 
the intervention observed in the study will be attained in the US primary 
care setting. 
 
Fair: The study differs from the US primary care 
population/situation/providers in a few ways that have the potential to affect 
the outcome in a clinically important way; it is only moderately probable 
(50%-89%) that the clinical experience with the intervention in the study 
will be attained in the US primary care setting. 
 
Poor: The study differs from the US primary care population/ situation/ 
providers in many way that have a high likelihood of affecting the clinical 
outcomes; the probability is low (<50%) that the clinical experience with the 
intervention observed in the study will be attained in the US primary care 
setting. 
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Table 7. Overall Quality 
 
Good Quality  Good internal and external validity 
Fair Quality  Good internal validity with fair external validity  
 Fair internal validity with Good external validity 
 Fair internal and external validity 
Poor Quality  Fair internal validity with poor external validity 
 Poor internal validity with fair external validity  
 Poor internal and external validity 
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Results 
A.  Literature Search 
The literature search identified 349 potentially relevant citations.  346 citations were 
found through electronic database searches and 3 articles were found through a targeted 
hand search. The initial Medline search identified 180 total abstracts.  CINAHL, BIOSIS, 
and COCHRANE searches identified 68, 88, and 10 abstracts respectively.  Twenty-three 
duplicate articles were identified across the searches and were discarded, resulting in 326 
unique and potentially relevant citations (Figure 1).  
 
I reviewed these 326 abstracts and excluded 314 articles (96%) for reasons including: 
inappropriate study design, metabolic syndrome was not the measured outcome, abstract 
was unavailable, second generation antipsychotics were not used as the intervention.  I 
attempted to retrieve the 12 remaining articles using resources from the University of 
North Carolina at Chapel Hill, Duke University, and North Carolina State University.  3 
of the articles were not accessible; therefore 9 articles underwent full text review.   
 
Upon full text review, 7 of the 9 articles were excluded.  Three of the excluded articles 
focused on comparing individual metabolic syndrome criteria (e.g. lipid and fasting 
glucose levels) between first- and second generation antipsychotics instead of metabolic 
syndrome 13-15. One study was excluded because the authors calculated incidence rate of 
developing diabetes instead of measuring incidence rate of developing metabolic 
syndrome 16.   One study was excluded because the authors did not compare development 
of metabolic syndrome between first- and second-generation antipsychotics 17.  The final 
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two studies that were excluded measured prevalence of developing metabolic syndrome 
instead of incidence 8, 18.   
 
The remaining two articles met eligibility criteria and were included for data abstraction 
and included in this review 19, 20.  The results of the literature search are depicted in Figure 
1.   
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Figure 1. Results of literature search 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Articles included in review: 
n=2 
1 randomized controlled study 
1 cohort study 
 
Citations Excluded by 
Abstract Review: 
n=314 
Unable to retrieve Full 
Text: 
n=3 
Full Text retrieved:  
n=9 
Citations Excluded by 
Full Text Review: 
n=7 
Titles and abstracts identified 
through database searches: 
n= 346 
Unique citations included in RefWorks:  
n=326 
# of additional records identified through 
targeted hand search: 
n= 3 
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B. Description of the Included Studies 
Both of the included studies were published in 2008.  One of the studies, a randomized 
controlled trial was conducted in the United States 20 and the other, a prospective cohort 
study, was conducted in Belgium 19.  The study from Belgium was restricted to patients 
from one site.  The study from the United States included participants from 57 different 
sites across the country including university clinics, state mental health agencies, VA 
Medical Centers, private nonprofit agencies, independent practice sites, and mixed 
system sites 20. 
 
Both of the included studies defined metabolic syndrome using the adapted guidelines set 
by the National Cholesterol Education Program Adult Treatment Panel III (NCEP ATP 
IIIa).  The measured outcome in both studies was metabolic syndrome.  The treatment 
intervention in one study included more than one second generation antipsychotic 
compared to one first generation antipsychotic 20.  The other study compared the 
intervention of several second generation antipsychotics with high potency first 
generation antipsychotics 19. The descriptive characteristics of the two included studies 
are depicted in Table 8. 
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Table 8. Characteristics of Included Studies 
First Author De Hert 19 Meyer 20 
Year Published 2008 2008 
Year Conducted Historical cohort: 1984-1995  
Concurrent cohort: 2000-2006 
January 2001  - December 2004 
Study Location University Centre St. Jozef, 
Kortenberg, Belgium. 
United States- 57 sites   
 16 university clinics, 
 10 state mental health 
agencies 
 7 VA Medical Centers 
 6 private nonprofit 
agencies 
 4 independent practice 
sites 
 14 mixed system sites 
Study Design Prospective cohort Randomized controlled trial 
Length of follow 
up time 
3 years 3 months 
Number of 
Participants 
Historic: 148        
Current:148 
Total: 296 
Source: 933 
All classifiable:660 
Fasting: 281 
Metabolic 
syndrome criteria 
used 
NCEP ATP-III a NCEP ATP-III a 
Intervention (SGA) Amisulpride 
Aripiprazole 
Clozapine 
Olanzapine 
Risperidone 
Quetiapine 
Olanzapine 
Risperidone 
Quetiapine 
Ziprasidone 
Comparison (FGA) High potency FGAs 
 Butyrophenones 
 Diphenylbutylperidines 
 Thioxanthenes 
Perphenazine 
Measured 
Outcome 
Metabolic Syndrome Metabolic Syndrome 
 
Abbreviations: SGA: Second generation antipsychotic agent; FGA: First generation 
antipsychotic agent; NCEP ATP-IIIa: Adapted National Cholesterol Education Program Adult 
Treatment Panel III criteria  
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C. Quality and Results of the Included Studies 
De Hert, Schreurs, Sweers et al. 19 
In their 2008 article in Schizophrenia Research, the authors compared two different 
cohorts (historic and current) of patients with schizophrenia admitted for their first 
episode of psychosis.   
 
The historic cohort was derived from an original cohort of 1119 consecutive patients 
diagnosed with schizophrenia or schizoaffective disorder admitted for their first episode 
of psychosis to two treatment and rehabilitation wards at University Centre St. Jozef, 
Kortenberg, Belgium between 1973 and 1992 21.  Laboratory testing for HDL cholesterol 
was not available until 1984; therefore the historic cohort only included patients after this 
point.  Furthermore, only patients with schizophrenia were included in the final study 
population.  Of the 301 patients admitted between 1984 and 1995, there was complete 
laboratory data for all metabolic criteria for 148 patients prior to start of treatment and 
these patients were included as the study population.  
 
The concurrent cohort was derived from a prospective cohort of consecutive patients 
admitted to the study between 2000 and 2006 at their first episode of psychosis in either 
in- or out-patient settings at a university psychiatric hospital and its affiliated facilities 22.   
De Hert, Schreurs, Sweers et al. matched the 148 patients from the historic cohort for age 
and sex with 148 patients in the current cohort. 
 
 
29 
At baseline measurement of the two cohorts, prior to starting antipsychotic treatment, the 
historic and current cohorts’ prevalence of metabolic syndrome were similar, 5.7% and 
5.6% respectively.  After 3 years of follow-up, the investigators of this study found that 
the incidence of metabolic syndrome had risen in both cohorts, but significantly more so 
in the second generation antipsychotic treated current cohort (historic: 9.8% vs. current: 
27.8%).  Of the 148 patients in each of the cohorts at the start of this study, complete data 
was available for 122 (historic cohort) and 108 (current cohort) patients after 3 years.   
 
Internal Validity 
The authors of this study did consider some of the potential confounders (age and sex) 
and adjusted for these when they assembled the current cohort to match the historic 
cohort.   However, this comparability was not maintained throughout the study as there 
was loss to follow up in both cohorts.  Specifically, the current cohort was younger at 
admission into the study and had a shorter duration of follow up (shorter amount of time 
on medication).   
 
To classify metabolic syndrome in the historic cohort, waist circumference was 
calculated using BMI and a “conservative conversion factor” which questions the 
accuracy of that variable in the historic cohort.  If the conversion factor was too 
conservative, then subjects who potentially had metabolic syndrome might have been 
misclassified making the reported incidence over 3 years for the historic cohort to be 
lower than it actually is.  Another limitation is that compared to the time period of the 
historic cohort, we are now more concerned about metabolic syndrome and the potential 
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of medications to cause changes to individual metabolic parameters which may result in 
closer monitoring of patients in the current cohort presenting a bias in measurement.  
Another limitation is that the authors did not collect data on compliance to medications in 
both cohorts.   Non-compliance to the medications might differential measurement bias 
especially if some of the drugs have worse side effects than the others.  Therefore, it 
would have been helpful to have information to quantify the specific effect of non-
compliance.  The authors of this study provided clear definition of interventions and 
outcomes.  They considered qualitatively the effect of confounding by differences in age 
and duration of treatment between the two cohorts in their discussion.  Follow up period 
was over three years which is fairly long in duration to appreciate long term effects of the 
medications.  This study was given a “fair” rating for internal validity. 
 
External Validity 
This study was conducted at one site in Belgium which limits the generalizability of the 
results.  People included in the study were of similar ethnic background (>95% Caucasian 
and of native Belgian origin). The definition of metabolic syndrome used in this study 
(NCEP IIIa) does not differentiate between different ethnic groups.  Even when using the 
IDP criteria where ethnicity is considered for waist circumference, criteria for USA 
populations are the same as the ATP IIIa values.  For European populations, however, 
there is a lower threshold for diagnosis of central obesity.  Given these definitions, the 
results can be considered to be conservative in diagnosis of metabolic syndrome and 
applicable to other ethnic groups.   
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Participants in this investigation were drug-naïve patients with schizophrenia, presenting 
with their first episode of psychosis.  Therefore, these results are not as applicable to 
patients with schizophrenia who are in a later stage of the disease, having been on 
antipsychotic medications for several years.  Lastly, another limitation to the 
generalizability of this study was that the size of the study population was fairly small.  
This study was given a “fair” rating for external validity. 
 
Overall quality 
There were some important limitations to consider with this study, including some loss of 
comparability between cohorts, loss to follow up, accuracy/validity of waist 
circumference measurements, and generalizability of results due to size of study 
population, study location, and number of study sites. For these concerns, this study was 
given a “fair” rating for overall quality. 
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Meyer, Davis, Goff et al.  20 
In their 2008 article in Schizophrenia research, Meyer, Davis, Goff et al. used data from 
phase I of the Clinical Antipsychotic Trials of Intervention and Effectiveness (CATIE) 
Schizophrenia trial to compare metabolic syndrome status in schizophrenia patients 
treated with antipsychotic medications.  Subjects in this trial were randomized to one of 
five treatments: olanzapine, risperidone, quetiapine, ziprasidone, and perphenazine.  
Baseline measures were completed prior to start of antipsychotic medication and follow 
up measures were completed at 3 months.   
 
Fasting measures were collected at both baseline and at 3 months for 281 subjects.  To 
have larger sample size, the authors created a cohort of non-fasting subjects whose 
metabolic syndrome status could be classified (“all classifiable cohort”) using modified 
metabolic syndrome criteria (n=660).  These two cohorts had similar demographics at 
baseline.  The authors reported prevalence measures of metabolic syndrome however 
enough data was reported in the article to determine incidence (Tables 9 and 10).   
 
In the fasting cohort, the overall incidence of metabolic syndrome over the 3 month 
period for those treated with second generation antipsychotics was 4.5% and for those 
treated with the first generation antipsychotic (perphenazine), there was a reduction in 
overall incidence by 3.8%.  For those treated with perphenazine, the number of cases 
decreased from 22 (baseline) to 20 (3 months). Within the second generation 
antipsychotic groups, there was variability.  The largest difference was between those 
treated with olanzapine and ziprasidone, the incidence of metabolic syndrome by the 3 
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month period was 9.5% in the olanzapine treated group and a decrease in incidence in the 
ziprasidone treated group by 9.7%.   
 
In the larger “all classifiable” cohort, the overall incidence of metabolic syndrome, over 
the 3 months, for those treated with second generation antipsychotics was 1.5% and for 
those treated with the first generation antipsychotic (perphenazine) was 0.8%.  Once 
again there was great variability in the second generation treatment groups.  Only 
olanzapine had a positive incidence at 9.1%.  Of the remaining second generation 
treatment groups, there were no new cases of metabolic syndrome in the risperidone 
treated group, one less case in the quetiapine group and finally, ziprasidone had the 
largest decrease in cases (6 cases) with a decrease in incidence by 7.8%. 
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Table 9. Results of fasting cohort 
Treatment n 
(n=278) 
Baseline 
prevalence  
# cases at 
baseline
a 
3 month 
prevalence  
# of total 
cases at 3 
months
b
  
Incident 
cases at 3 
months 
c 
Incidence 
(%)
d 
Olanzapine 74 0.419 31 0.514 38 7 9.5 
Risperidone 54 0.370 20 0.426 23 3 5.6 
Quetiapine 67 0.388 26 0.433 29 3 4.5 
Ziprasidone 31 0.484 15 0.387 12 -3 -9.7 
Total SGA 226     10 4.5 
FGA: 
Perphenazine 
52 0.423 22 0.385 20 -2 -3.8 
Abbreviations: SGA: Second generation antipsychotic agent; FGA: First generation 
antipsychotic agent 
Table 10. Results of the “all classifiable” cohort 
Treatment  n 
(n=660) 
Baseline 
prevalence  
# cases at 
baseline
a 
3 month 
prevalence  
# of total 
cases at 3 
months
b 
Incident 
cases at 3 
months 
c 
Incidence 
(%)
d 
Olanzapine 164 0.348 57 0.439 72 15 9.1 
Risperidone 147 0.306 45 0.306 45 0 0 
Quetiapine 143 0.378 54 0.371 53 -1 -0.7 
Ziprasidone 77 0.377 29 0.299 23 -6 -7.8 
Total SGA 531     8 1.5 
FGA: 
Perphenazine 
129 0.372 48 0.380 49 1 0.8 
Abbreviations: SGA: Second generation antipsychotic agent; FGA: First generation 
antipsychotic agent 
 
Note: The following represents calculations used in Tables 9 and 10. 
a. # of cases at baseline = n* Baseline prevalence 
b. # of cases at 3 months = n* 3 month prevalence 
c. Incident cases at 3 months = # of cases at 3 months - # of cases at baseline 
d. Incidence (%) = [(Incident cases at 3 months) ÷ n] * 100% 
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Internal Validity 
Meyer, Davis, Goff et al. clearly defined the interventions as well as the outcomes in this 
study.  Randomization to the five antipsychotic medications was conducted under double 
blind conditions.  The authors compared baseline demographics between the fasting 
cohort (n=281), the larger “all classifiable” cohort (n=660), and the source population of 
all the subjects in the CATIE phase 1 trial with some data at baseline and 3 months 
(n=933).  Within these cohorts, there were no differences in baseline demographics.  The 
authors however failed to report baseline demographics within the different treatment 
arm which is a significant limitation as we do not know how comparable the treatment 
arms are to each other.  The authors did report the baseline prevalence of each of the 
metabolic criteria for the different treatment arms in the fasting cohort; the criteria were 
fairly comparable between all groups.    
 
Another limitation is that baseline data on length of previous antipsychotic use was not 
collected.  Subjects who may have a longer exposure to metabolically effecting 
antipsychotics will more likely have metabolic syndrome.  If these subjects are unequally 
randomized, the results may be skewed towards the treatment arm with more subjects that 
were exposed for a longer period of time prior to start of the study.  Additionally, the 
authors did not do an intention to treat analysis, severely limiting this readers’ ability to 
determine whether randomization was intact throughout the study.   
 
For the fasting cohort, the measurements were equal, valid, and reliable.  For the “all 
classifiable” cohort, there are some questions about the measurements used for 
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classification of metabolic syndrome.  This cohort included patients that had non-fasting 
data.  Of the five metabolic syndrome criteria, serum glucose and triglycerides are 
affected by fasting status.  For serum glucose, the authors considered the criteria to have 
been met if the subject was currently taking hypoglycemic medications or insulin or if the 
random glucose level was ≥200mg/dl which met the American Diabetes Association 
definition for DM.  Furthermore, glucose criteria was not considered met if the random 
glucose was <100 mg/dl.  For triglyceride levels, the criterion was considered not met if 
the random triglyceride level was <150 mg/dl.  Additionally, any subject not taking anti-
diabetic medication, with a random glucose value between 100-199 mg/dl and random 
triglyceride level ≥150 mg/dl were not considered either positive or negative for 
metabolic criteria 20.  These modified criteria could potentially lead to underestimation of 
incidence as some people who may actually have metabolic syndrome are classified as 
not having metabolic syndrome.   
 
This study was given a rating of “poor” for inappropriately comparing the initially 
assembled groups, not conducting an intention to treat analysis, and concerns of unequal 
and invalid measurements. 
 
External Validity 
Data for this study were collected at 57 sites in the United States in various different 
settings increasing the generalizability of the results.  The fasting cohort was limited by 
the small size of each of the treatment groups.   As mentioned previously, the length of 
prior treatment with other antipsychotic medications was unknown; therefore we cannot 
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determine the stage of the disease of the participants in this study.  In regard to situation 
and providers, they can be easily reproduced in the general settings.  This study was 
given a “fair” rating. 
 
Overall Quality 
Given the considerable limitations of this study resulting in “poor” internal and “fair” 
external validity, this study was given a “poor” overall quality rating 
 
D. Principal Findings of this Review 
In summary, one study 19found a significantly higher incidence of metabolic syndrome in 
those taking second generation antipsychotics than in those taking first generation 
antipsychotics.  This study was given an overall quality rating of “fair.”  The other study 
20showed mixed results.  In one cohort of fasting patients, they found a higher incidence 
of metabolic syndrome in those treated with second generation antipsychotics, whereas in 
the other cohort using non-fasting criteria, the authors found a small difference in overall 
incidence between first- and second-generation antipsychotics, with slightly higher 
incidence in the second generation antipsychotic group.  This study was given an overall 
quality rating of “poor” due to some significant limitations in internal and external 
validity.   
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Discussion 
A. Synthesis of Results 
There is poor to fair evidence that there is increased incidence of developing metabolic 
syndrome in patients with schizophrenia being treated with second generation 
antipsychotics when compared to patients with schizophrenia treated with first generation 
antipsychotics.  Of the two studies included in this systematic review, one was of fair 
quality and the other was of poor quality.   
 
B. Secondary results 
The study by Meyer, Davis, Goff et al. 20,which was given a poor quality rating, also 
found differences in incidence of developing metabolic syndrome between individual 
second generation antipsychotic treatments.  They found that olanzapine was associated 
with an increased incidence of developing metabolic syndrome over a 3 month period 
over the remaining second generation antipsychotics under study (risperidone, quetiapine, 
ziprasidone). 
 
C. Limitations of review 
This review has several limitations.  Firstly, the search for relevant articles was limited to 
only include English-language articles.  Antipsychotic medications are the primary 
source of treatment for schizophrenia and as such there may be studies that are published 
in other languages that may be appropriate for answering the question proposed in this 
systematic review.  Therefore, this review might be slightly limited by excluding these 
articles.   
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Additionally, this systematic review was limited to currently published literature.  There 
are likely unpublished data and ongoing trials studying incidence of metabolic syndrome 
in antipsychotic treated schizophrenic patients and these was not included in this review.  
Furthermore, there were 3 articles identified by the abstract review that were not able to 
be retrieved.  Exclusion of these articles limits the comprehensiveness of this systematic 
review.   
 
D. Recommendations for future research 
The two studies included in this review had several limitations.  For future research, there 
is a need for a more optimally constructed and conducted study.  Randomized controlled 
trials would work best as specific interventions and controls can be assigned randomly 
and confounders can be limited easily at the start of the studies.  Non-randomized cohort 
trials could also be appropriate as long as there is proper control of confounders.  In order 
to best determine if people with schizophrenia treated with second generation 
antipsychotics have a higher incidence of developing metabolic syndrome, we must first 
start with schizophrenia patients that are drug naïve presenting with their first episode of 
psychosis.  These patients would not have any prior antipsychotic use limiting 
confounding effects from different drugs.   
 
Although follow-up of 3 months is a requirement for this review, in general, patients with 
schizophrenia are treated of long periods of time; therefore, a longer follow up period 
would be more appropriate.  The ideal follow up period would be the lifetime of the 
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included patients.  This is because drug-naïve, first episode of psychosis patients with 
schizophrenia tend to be young and healthy.  Furthermore, the risk of metabolic 
syndrome increases with age and needs to be considered in the study.  In other words, 
differential risk across first generation antipsychotics and second generation 
antipsychotics should be evaluated over the course of the disease process of 
schizophrenia. 
 
In terms of interventions, some studies have indicated the variable effects of different 
second generation antipsychotics on metabolic parameters (weight gain, impaired fasting 
glucose) 6.  One of the studies included in this review randomized people to four different 
second generation antipsychotics, but only randomized to one first generation 
antipsychotic agent 20.  Ideally, we would randomize patients to several commonly used 
second generation antipsychotic agents and several first generation antipsychotic agents.  
This would enable comparison of the drug class effects of first- and second-generation 
antipsychotics as well as the differential effects of individual agents.   
 
Additionally, much of the literature on this topic is in smaller sample sizes from one site.  
This limits the generalizability of the results to a larger population in different locations.  
Therefore, it would preferable to conduct a multi-site, multi-national study utilizing a 
large study population.   
 
 
 
 
41 
E. Conclusions 
In conclusion, the available evidence is insufficient to determine whether treatment with 
second generation antipsychotic agents results in a higher incidence of developing 
metabolic syndrome than treatment with first generation antipsychotic agents in patients 
with schizophrenia.  Nonetheless, there is need for future studies with better design as 
current studies are not of good quality.   
 
I have described areas in future research that would improve on the current available 
literature and have described an ideal study which could be readily conducted if funding 
were not an issue.  A long-term, large, multi-site, multi-national, randomized controlled 
trial would be very expensive.  Drug companies which have the funds would not be 
interested in this study as the study is looking for adverse effects of medications.  
Therefore, funding for the study would have to come from a source such as the NIH.   
Funding for such an extensive study is further limited by the current status of the 
economy.  The limited numbers of studies included in this review are likely due in part to 
barriers in cost.    
 
Metabolic syndrome and schizophrenia are chronic conditions for which treatment is long 
term.  They both have a significant effect on the quality of life of those that are affected.  
The second generation antipsychotic medications have only been on the market for the 
past two decades and long-term effects of these medications are only now being realized.  
Therefore, only with more studies of better quality, can we determine the specific effect 
of antipsychotic medications on developing metabolic syndrome.   
 
42 
Appendix I. Search Strategy 
1. PubMed Search using MeSH headings and keywords: 
 
(("Antipsychotic Agents"[Mesh] OR ("antipsychotic agents"[MeSH Terms] OR 
("antipsychotic"[All Fields] AND "agents"[All Fields]) OR "antipsychotic 
agents"[All Fields] OR "antipsychotic"[All Fields] OR "antipsychotic 
agents"[Pharmacological Action]) OR ("antipsychotic agents"[MeSH Terms] OR 
("antipsychotic"[All Fields] AND "agents"[All Fields]) OR "antipsychotic 
agents"[All Fields] OR "antipsychotics"[All Fields] OR "antipsychotic 
agents"[Pharmacological Action])) AND (atypical[All Fields] OR "second 
generation"[All Fields])) AND ("Metabolic Syndrome X"[Mesh] OR "metabolic 
syndrome"[All Fields]) AND (English[lang]) 
 
2. CINAHL via EBSCO host: 
Boolean/Phrase: (MH “Antipsychotic Agents +”) AND (MH “Metabolic 
Syndrome X+”)  
 
3. BIOSIS and The Cochrane Library: 
 
 “Antipsychotic Agents” AND “Metabolic Syndrome” 
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Appendix 2. Evidence table of included studies 
Author De Hert 19 Meyer 20 
Year Published 2008 2008 
Study Design 2 cohorts- prospective RCT 
Selection bias Dropouts: Historic: 26  Current: 40  
 
Historic: older and longer  
Current: younger, and shorter duration   
 
Did not collect exact drugs, switches over 
time between agents or eventual 
polypharmacy in historic cohort 
Did not conduct intention to treat 
analysis 
 
Baseline demographics and 
characteristics between treatment 
arms were not discussed in the study 
Measurement bias Used a conversion to calculate waist 
circumference from BMI for Historic 
cohort.   
 
Lab techniques have changed over time.  
We are more careful now about 
metabolic syndrome and so we look for it 
more 
For all classifiable cohort: Modified 
criteria for impaired fasting glucose 
and triglycerides 
 
The duration of baseline 
antipsychotic use was not measured- 
important as those with longer 
exposure to more metabolically 
offending agents might have been 
randomized unequally to the 
different treatment arms. 
Internal validity 
(Good, Fair, Poor) 
Fair Poor 
External validity Fair: 
 >95% Caucasian and of native 
Belgian origin 
 One hospital center  
 Small sample size 
Fair 
 57 sites in US. Large study.- 
generalizable 
 Small sample size of 
treatment groups in fasting 
cohort 
Quality of the Study Fair Poor 
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